An inflammation-targeting hydrogel for local drug delivery in inflammatory bowel disease
暂无分享,去创建一个
Robert Langer | Giovanni Traverso | Matthew J. Hamilton | Jeffrey M. Karp | Marc D. Succi | J. Karp | R. Langer | J. Korzenik | L. Glimcher | G. Traverso | J. Glickman | P. Vemula | Sufeng Zhang | M. Succi | Laurie H. Glimcher | Jonathan N. Glickman | Sufeng Zhang | J. Ermann | Joerg Ermann | Joshua R. Korzenik | M. Hamilton | Allen Zhou | Bonnie Cao | Praveen K. Vemula | B. Cao | Allen Zhou | Bonnie Cao
[1] D. Hui,et al. Modified Low Density Lipoprotein Enhances the Secretion of Bile Salt-stimulated Cholesterol Esterase by Human Monocyte-Macrophages , 1997, The Journal of Biological Chemistry.
[2] Y. Barenholz,et al. Enhanced Transferrin Receptor Expression by Proinflammatory Cytokines in Enterocytes as a Means for Local Delivery of Drugs to Inflamed Gut Mucosa , 2011, PloS one.
[3] J. Lutkenhaus,et al. Confinement Effects on Cross-Linking within Electrostatic Layer-by-Layer Assemblies Containing Poly(allylamine hydrochloride) and Poly(acrylic acid) , 2010 .
[4] Wendy S. Garrett,et al. Communicable Ulcerative Colitis Induced by T-bet Deficiency in the Innate Immune System , 2007, Cell.
[5] O. Levy,et al. Lipid mediator-induced expression of bactericidal/ permeability-increasing protein (BPI) in human mucosal epithelia , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[6] D. Priebat,et al. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. , 1982, The Journal of investigative dermatology.
[7] A. Feller,et al. Human β-defensin 2 but not β-defensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel disease , 2002 .
[8] J. Samet,et al. Food and Drug Administration , 2007, BMJ : British Medical Journal.
[9] L. Glimcher,et al. Nod/Ripk2 signaling in dendritic cells activates IL-17A–secreting innate lymphoid cells and drives colitis in T-bet−/−.Rag2−/− (TRUC) mice , 2014, Proceedings of the National Academy of Sciences.
[10] S. V. van Deventer,et al. Inflammatory bowel disease is associated with increased mucosal levels of bactericidal/permeability-increasing protein. , 1996, Gastroenterology.
[11] D. Hommes,et al. Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists , 2007, Molecular and Cellular Endocrinology.
[12] J. Karp,et al. A single localized dose of enzyme-responsive hydrogel improves long-term survival of a vascularized composite allograft , 2014, Science Translational Medicine.
[13] J. Hanes,et al. Enhanced adhesion of ligand‐conjugated biodegradable particles to colitic venules , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[14] Y. Barenholz,et al. Differential Adhesion of Normal and Inflamed Rat Colonic Mucosa by Charged Liposomes , 2004, Pharmaceutical Research.
[15] Y. Barenholz,et al. Local treatment of experimental colitis in the rat by negatively charged liposomes of catalase, TMN and SOD , 2006, Journal of drug targeting.
[16] G. Dalmasso,et al. Temporal and Spatial Analysis of Clinical and Molecular Parameters in Dextran Sodium Sulfate Induced Colitis , 2009, PloS one.
[17] E. Loftus. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. , 2004, Gastroenterology.
[18] Kojiro Matsumoto,et al. Binding of sialyl Lewis X antigen to lectin-like receptors on NK cells induces cytotoxicity and tyrosine phosphorylation of a 17-kDa protein. , 2006, Biochimica et biophysica acta.
[19] T. Davies. A Mechanistic Update , 1990 .
[20] J. Hubbell,et al. Enhanced proteolytic degradation of molecularly engineered PEG hydrogels in response to MMP-1 and MMP-2. , 2010, Biomaterials.
[21] Aliasger K Salem,et al. Leukocyte-inspired biodegradable particles that selectively and avidly adhere to inflamed endothelium in vitro and in vivo , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[22] Didier Merlin,et al. Orally delivered thioketal nanoparticles loaded with TNF-α-siRNA target inflammation and inhibit gene expression in the intestines. , 2010, Nature materials.
[23] Y. Barenholz,et al. Transferrin as a luminal target for negatively charged liposomes in the inflamed colonic mucosa. , 2009, Molecular pharmaceutics.
[24] Jian Jiao,et al. Anti-inflammatory effect of Diammonium Glycyrrhizinate in a rat model of ulcerative colitis. , 2006, World journal of gastroenterology.
[25] A. Day,et al. Defensins and inflammation: The role of defensins in inflammatory bowel disease , 2009, Journal of gastroenterology and hepatology.
[26] G. Amidon,et al. Drug targeting strategies for the treatment of inflammatory bowel disease: a mechanistic update , 2010, Expert review of clinical immunology.
[27] Subrata Ghosh,et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. , 2012, Gastroenterology.
[28] L. Sorokin. The impact of the extracellular matrix on inflammation , 2010, Nature Reviews Immunology.
[29] F. Zijlstra,et al. The effect of dexamethasone treatment on murine colitis. , 2000, Scandinavian journal of gastroenterology.
[30] A. Kornbluth,et al. Ulcerative colitis practice guidelines in adults , 1997 .
[31] E. Mazzon,et al. Glucocorticoid-induced leucine zipper is protective in Th1-mediated models of colitis. , 2009, Gastroenterology.
[32] Subrata Ghosh,et al. Impact of inflammatory bowel disease on quality of life: Results of the European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA) patient survey. , 2007, Journal of Crohn's & colitis.
[33] M. Vatn,et al. Health‐Related Quality of Life in Patients with Ulcerative Colitis After a 10‐year Disease Course: Results from the IBSEN Study , 2012, Inflammatory bowel diseases.
[34] W. Falk,et al. Neutralization of tumour necrosis factor (TNF) but not of IL‐1 reduces inflammation in chronic dextran sulphate sodium‐induced colitis in mice , 1997, Clinical and experimental immunology.
[35] A. Metters,et al. Synthetic matrix metalloproteinase-sensitive hydrogels for the conduction of tissue regeneration: Engineering cell-invasion characteristics , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[36] J. Rinehart,et al. Nanoparticles Containing Anti-inflammatory Agents as Chemotherapy Adjuvants: Optimization and In Vitro Characterization , 2008, The AAPS Journal.
[37] L. Lix,et al. Predictors of Medication Adherence in Inflammatory Bowel Disease , 2007, The American Journal of Gastroenterology.
[38] O. Svensson,et al. Interactions between chitosan-modified particles and mucin-coated surfaces. , 2008, Journal of colloid and interface science.
[39] D. Weitz,et al. On-demand drug delivery from self-assembled nanofibrous gels: a new approach for treatment of proteolytic disease. , 2011, Journal of biomedical materials research. Part A.
[40] S. Tsurufuji,et al. The role of glucocorticoid receptor and gene expression in the anti-inflammatory action of dexamethasone , 1979, Nature.
[41] E. Wiener,et al. Macrophage Cultures: An Extracellular Esterase , 1968, Science.
[42] Y. Kawashima,et al. Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. , 2001, The Journal of pharmacology and experimental therapeutics.
[43] A. Kornbluth,et al. Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee , 2010, The American Journal of Gastroenterology.